199 related articles for article (PubMed ID: 24648800)
1. Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis.
Lee JH; Oh MH; Park JS; Na GJ; Gil HW; Yang JO; Lee EY; Hong SY
Korean J Intern Med; 2014 Mar; 29(2):176-82. PubMed ID: 24648800
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator receptor in IgA nephropathy.
Ahn SY; Chin HJ
Korean J Intern Med; 2014 Mar; 29(2):166-9. PubMed ID: 24648797
[No Abstract] [Full Text] [Related]
3. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Fuessel S; Erdmann K; Taubert H; Lohse-Fischer A; Zastrow S; Meinhardt M; Bluemke K; Hofbauer L; Fornara P; Wullich B; Baretton G; Magdolen V; Wirth MP; Kotzsch M
BMC Cancer; 2014 Dec; 14():974. PubMed ID: 25519168
[TBL] [Abstract][Full Text] [Related]
4. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas.
Ulisse S; Baldini E; Mottolese M; Sentinelli S; Gargiulo P; Valentina B; Sorrenti S; Di Benedetto A; De Antoni E; D'Armiento M
BMC Cancer; 2010 Apr; 10():151. PubMed ID: 20403162
[TBL] [Abstract][Full Text] [Related]
6. Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients.
Taubert H; Würl P; Greither T; Kappler M; Bache M; Lautenschläger C; Füssel S; Meye A; Eckert AW; Holzhausen HJ; Magdolen V; Kotzsch M
Br J Cancer; 2010 Feb; 102(4):731-7. PubMed ID: 20051950
[TBL] [Abstract][Full Text] [Related]
7. Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated β1-integrin endocytosis.
Kobayashi N; Ueno T; Ohashi K; Yamashita H; Takahashi Y; Sakamoto K; Manabe S; Hara S; Takashima Y; Dan T; Pastan I; Miyata T; Kurihara H; Matsusaka T; Reiser J; Nagata M
Am J Physiol Renal Physiol; 2015 Mar; 308(6):F614-26. PubMed ID: 25587125
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC).
Janisch F; D'Andrea D; Iwata T; Kimura S; Abufaraj M; Enikeev D; Glybochko PV; Karakiewicz PI; Nyirady P; Fajkovic H; Haitel A; Seebacher V; Rink M; Shariat SF
Urol Oncol; 2020 May; 38(5):423-432. PubMed ID: 32209281
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
10. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
Chambers SK; Gertz RE; Ivins CM; Kacinski BM
Cancer; 1995 Apr; 75(7):1627-33. PubMed ID: 8826920
[TBL] [Abstract][Full Text] [Related]
11. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB
J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients.
Halamkova J; Kiss I; Pavlovsky Z; Jarkovsky J; Tomasek J; Tucek S; Hanakova L; Moulis M; Cech Z; Zavrelova J; Penka M
Hepatogastroenterology; 2011; 58(112):1918-25. PubMed ID: 22234062
[TBL] [Abstract][Full Text] [Related]
13. Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
Andres SA; Edwards AB; Wittliff JL
J Clin Lab Anal; 2012 Feb; 26(2):93-103. PubMed ID: 22467324
[TBL] [Abstract][Full Text] [Related]
14. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A
J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395
[TBL] [Abstract][Full Text] [Related]
16. Association of uPA, PAT-1, and uPAR in nipple aspirate fluid (NAF) with breast cancer.
Qin W; Zhu W; Wagner-Mann C; Folk W; Sauter ER
Cancer J; 2003; 9(4):293-301. PubMed ID: 12967140
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
Kumamoto H; Ooya K
J Oral Pathol Med; 2007 Sep; 36(8):488-94. PubMed ID: 17686008
[TBL] [Abstract][Full Text] [Related]
18. mRNA expression of urokinase and plasminogen activator inhibitor-1 in human crescentic glomerulonephritis.
Lee HS; Park SY; Moon KC; Hong HK; Song CY; Hong SY
Histopathology; 2001 Aug; 39(2):203-9. PubMed ID: 11493338
[TBL] [Abstract][Full Text] [Related]
19. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
[TBL] [Abstract][Full Text] [Related]
20. Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer.
Kimura S; D'Andrea D; Iwata T; Foerster B; Janisch F; Parizi MK; Moschini M; Briganti A; Babjuk M; Chlosta P; Karakiewicz PI; Enikeev D; Rapoport LM; Seebacher V; Egawa S; Abufaraj M; Shariat SF
World J Urol; 2020 Oct; 38(10):2501-2511. PubMed ID: 31797075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]